Novo Nordisk's Uphill Battle After Eli Lilly's strong earnings report and promising drug developments, investors will be watching Novo Nordisk carefully when it reports its own Q1 2026 earnings
Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome
Additionally, it is worth noting that the specificity of metabolomic profiles need to be investigated in disease controls, and the heterogenous nature of ME/CFS may mean different ME/CFS subtypes could have different metabolomic profiles, which requires further investigation for diagnostic application
Oral medications may feel easier to obtain, easier to hide, and easier to misuse
Some people experience increases under 5 BPM while others see increases above 10 BPM
You can subscribe to the show here on Apple Podcasts, or Google Podcasts, or Spotify, or any app of your choice